Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vince Burgess Steps Down After Nine Years As Acutus CEO

CFO David Roman Will Be Acutus' Interim CEO

Executive Summary

Analysts believe the company’s arrythmia mapping technology could potentially disrupt the electrophysiology mapping market, but are disappointed with Acutus’ growth so far.

You may also be interested in...



Acutus Names David Roman As New CEO; Mickelsen Departs Company

After announcing that its estimated second-quarter 2022 revenue exceeded analysts’ expectations, Acutus announced that David Roman, the interim CEO and CFO, is now the permanent CEO. Also, Steven Mickelsen announced that he is stepping down as Acutus’ chief translational science officer.

Acutus Sells Left-Heart Access Business To Medtronic; Extends Its Cash Runway

The deal, potentially worth more than $85m, will allow Acutus to get more revenue from its core AcQMap electrophysiology mapping technology and invest in the development of its pulsed field ablation system.

Acutus Cuts Jobs To Reduce Cash Burn, Drive Adoption Of Cardiac Mapping System

The electrophysiology company announced it will reduce its workforce and take other cost-reduction measures to reduce its annual spending by $23m-$25m. Analysts suspect the company will need to raise more money from investors in 2022 or try to be acquired by a larger company.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel